Status:
COMPLETED
High Dose Somatostatin Analogues in Neuroendocrine Tumors
Lead Sponsor:
Federico II University
Collaborating Sponsors:
University of Perugia, Faculty of Medicine, Department of Internal Medicine
University of Genova
Conditions:
Respiratory Tract Neoplasms
Thymic Neoplasms
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
Octreotide (OCT) is a somatostatin analogue (SSA) available in a long-acting formulation, conventionally administered every 28 days at the maximum dose of 30 mg. Together with lanreotide, it is consid...
Detailed Description
The patient population will include the patients with a histologically documented diagnosis of WDNET, defined according to the last WHO Classification criteria for NET of gastro-entero-pancreatic, bro...
Eligibility Criteria
Inclusion
- Well differentiated neuroendocrine tumors in disease progression
Exclusion
- Well differentiated neuroendocrine tumors without disease progression
- Patients with intolerance to somatostatin analogues
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT00990535
Start Date
January 1 2006
End Date
December 1 2008
Last Update
October 7 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Federico II of Naples
Naples, Italy, 80131